Avanafil Patent Expiration
Avanafil is Used for treating erectile dysfunction. It was first introduced by Metuchen Pharmaceuticals Llc
Avanafil Patents
Given below is the list of patents protecting Avanafil, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Stendra | US6656935 | Aromatic nitrogen-containing 6-membered cyclic compounds | Apr 27, 2025 | Metuchen Pharms |
| Stendra | US7501409 | Preparations for oral administration |
May 05, 2023
(Expired) | Metuchen Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Avanafil's patents.
Latest Legal Activities on Avanafil's Patents
Given below is the list recent legal activities going on the following patents of Avanafil.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 27 Aug, 2020 | US7501409(Litigated) |
| Patent Term Extension Certificate Critical | 18 Mar, 2016 | US6656935(Litigated) |
| Notice of Final Determination -Eligible | 18 Nov, 2015 | US6656935(Litigated) |
| FDA Final Eligibility Letter Critical | 21 Jan, 2015 | US6656935(Litigated) |
| transaction for FDA Determination of Regulatory Review Period | 10 Jun, 2014 | US6656935(Litigated) |
| transaction for FDA Determination of Regulatory Review Period | 09 May, 2014 | US6656935(Litigated) |
| Second letter to regulating agency to determine regulatory review period | 19 Mar, 2014 | US6656935(Litigated) |
| Letter from FDA or Dept of Agriculture re PTE application | 13 Feb, 2013 | US6656935(Litigated) |
| Initial letter Re: PTE Application to regulating agency | 28 Sep, 2012 | US6656935(Litigated) |
| Patent Term Extension Application under 35 USC 156 Filed | 18 Jun, 2012 | US6656935(Litigated) |
Avanafil's Family Patents
Explore Our Curated Drug Screens
Avanafil Generic API Manufacturers
Several generic applications have been filed for Avanafil.
Given below is the list of companies who have filed for Avanafil generic, along with the locations of their manufacturing plants worldwide.
1. HETERO LABS LTD V
Hetero Labs Ltd Unit V has filed for 3 different strengths of generic version for Avanafil. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd V.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 50MG | tablet | Prescription | ORAL | AB | Jun 14, 2024 |
| 100MG | tablet | Prescription | ORAL | AB | Jun 14, 2024 |
| 200MG | tablet | Prescription | ORAL | AB | Jun 14, 2024 |